University System of Maryland

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Other

The United States of America As Represented by the Department of Health

Mcdaniel College

Edward A Sausville

Rena S Lapidus

Ashkan Emadi

Brandon Carter-Cooper

Laurent Meijer

Dana Victor Ferraris

Dvorit Samid

William J Murphy

Steven Fletcher

B Rao Vishnuvajjala

Charles E Myers

Joost J Oppenheim

Kenneth M Snader

Venkatachala L Narayanan

Conrad Kunick

Rick Gussio

Jane B Trepel

Robert R Redfield

John D Minna

Alonso Heredia

O M Zack Howard

Ravi Kumar Jalluri

Melinda G Hollingshead

Alexandra Miller

Charles Davis

Ronald Gartenhaus

Mariola Sadowska

Gurmeet Kaur

Ravi K Varma

Daniel W Zaharevitz

Angelika M Burger

Jean Viallet

Gregory Curt

The invention relates to new amino dimeric naphthoquinone compounds with antileukemic activity. Compounds of the invention demonstrated increased aqueous solubility compared to previously available dimeric naphthoquinones and potent nanomolar inhibition of cell survival in AML cells. Preferred compounds contained an aziridine or a secondary amino alcohol pharmacophore.

Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia

Methods are provided for treating HIV and cancer in a subject in need thereof by administering to the subject therapeutically effective amounts of an mTOR inhibitor. Other methods are provided for treating subjects infected with HIV by administering to the subject therapeutically effective amounts of the mTOR inhibitor INK128, GSK2126458, AZD2014 or Torin-2.

Treatment agents for inhibiting HIV and cancer in HIV infected patients

The present invention provides a formulation comprising dichloroacetate and arsenic trioxide. The present invention also provides a method of treating cancer by administering a therapeutically effective amount of dichloroacetate and arsenic trioxide.

Compositions and methods for the treatment of cancers

The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-&#x3b1; in plasma. Additional methods concern determining levels of Hsp90-associated molecules.

Use of plasma HSP90 related to malignancy

Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the disclosure, without limitation, satisfy either Formula 1 or Formula 2.The present disclosure also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs and potentially comprising other active ingredients, other materials conventionally used in the formulation of pharmaceutical compositions, and mixtures thereof. The compounds and compositions of the disclosure can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.

Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs

A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.

Geldanamycin derivative and method of treating cancer using same

Fused azepinone cyclin dependent kinase inhibitors

A method of using a ureido derivative of a poly-4-amino-2-carboxy-1-methyl pyrrole or a pharmaceutically acceptable salt thereof to inhibit inflammation, particularly non-TNF-&agr; dependent inflammation, in a mammal.

Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammation

The invention provides methods of treating cancer including administering an effective amount of selected terpenes to a mammal having the cancer when the cancer is prostate cancer, colon cancer, astrocytoma, or sarcoma. The terpene is selected from the group consisting of a cyclic monoterpene, a noncyclic monoterpene, a noncyclic sesquiterpene and a noncyclic diterpene. The invention also provides a method of sensitizing a cancer to radiation including administering an effective amount of a terpene to a mammal having the cancer wherein the terpene is selected from the group noted above. Additionally, the invention provides methods of inhibiting the growth of cancer cells including applying an effective amount of a selected terpene to the cancer cells which are cells of prostate cancer, colon cancer, osteosarcoma, or glioblastoma.

Monoterpenes, sesquiterpenes and diterpenes as cancer therapy

The invention is to a method of treating malignancies with cholera toxin after determining if labelled beta subunit cholera toxin binds to the tissue.

Inhibition of malignant cells having G.sub.M1 ganglo-side sites by

Growing community of inventors

Silver Spring, MD, United States of America

Edward A Sausville